Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
Journal of Hypertension|May 11, 2012
Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trialMarkolf Hanefeld, Frank Pistrosch, Carsta Koehler, et al.
Metabolism: Clinical and Experimental|August 30, 2005
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitusElena Henkel, Mario Menschikowski, Carsta Koehler, et al.
American Journal of Hypertension|May 9, 2007
Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patientsFrank Pistrosch, Eva Reissmann, Jan Wildbrett, et al.
Cardiovascular Diabetology|July 16, 2011
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB studyMarkolf Hanefeld, Andreas Pfützner, Thomas Forst, et al.
Clinical Nephrology|December 22, 2011
Urinary tract infection in patients with diabetes mellitusReinhard Fünfstück, Lindsay E Nicolle, Markolf Hanefeld, et al.
Journal of Diabetes Science and Technology|May 31, 2014
Differences in Glycemic Variability Between Normoglycemic and Prediabetic SubjectsMarkolf Hanefeld, Stefan Sulk, Matthias Helbig, et al.
Cardiovascular Diabetology|April 28, 2007
Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) studyMarkolf Hanefeld, Carsta Koehler, Silvina Gallo, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 3, 2007
Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysisElena Henkel, Sarsta Gallo, Gilvina Siegert, et al.
Clinical Chemistry and Laboratory Medicine|May 8, 2013
A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytesAnne Hellwig, Anja Scherber, Carsta Koehler, et al.
Reviews in Endocrine & Metabolic Disorders|March 10, 2016
The metabolic vascular syndrome - guide to an individualized treatmentMarkolf Hanefeld, Frank Pistrosch, Stefan R Bornstein, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
Journal of Hypertension|May 11, 2012
Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trialMarkolf Hanefeld, Frank Pistrosch, Carsta Koehler, et al.
Metabolism: Clinical and Experimental|August 30, 2005
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitusElena Henkel, Mario Menschikowski, Carsta Koehler, et al.
American Journal of Hypertension|May 9, 2007
Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patientsFrank Pistrosch, Eva Reissmann, Jan Wildbrett, et al.
Cardiovascular Diabetology|July 16, 2011
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB studyMarkolf Hanefeld, Andreas Pfützner, Thomas Forst, et al.
Clinical Nephrology|December 22, 2011
Urinary tract infection in patients with diabetes mellitusReinhard Fünfstück, Lindsay E Nicolle, Markolf Hanefeld, et al.
Journal of Diabetes Science and Technology|May 31, 2014
Differences in Glycemic Variability Between Normoglycemic and Prediabetic SubjectsMarkolf Hanefeld, Stefan Sulk, Matthias Helbig, et al.
Cardiovascular Diabetology|April 28, 2007
Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) studyMarkolf Hanefeld, Carsta Koehler, Silvina Gallo, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 3, 2007
Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysisElena Henkel, Sarsta Gallo, Gilvina Siegert, et al.
Clinical Chemistry and Laboratory Medicine|May 8, 2013
A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytesAnne Hellwig, Anja Scherber, Carsta Koehler, et al.
Reviews in Endocrine & Metabolic Disorders|March 10, 2016
The metabolic vascular syndrome - guide to an individualized treatmentMarkolf Hanefeld, Frank Pistrosch, Stefan R Bornstein, et al.
Pageof 13